American Society of Hematology

Schedule and Program for the 2018 ASH Summit on Emerging Immunotherapies

The following programming corresponds to the 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases.

8:00 a.m. – 7:00 p.m.
Registration
8:00 a.m. – 8:45 a.m.
Breakfast and Exhibits
9:05 a.m. – 11:05 a.m.
Cellular Therapies and Their Role in the Treatment of Malignant and Non-Malignant Hematologic Disease

Chair:
Jeffrey S. Miller, MD, University of Minnesota

Speakers:
Stanley R. Riddell, MD, Fred Hutchinson Cancer Research Center
Strategies to Improve Safety and Efficacy of CAR T Cells in Hematologic Malignancies

Helen E. Heslop, MD, DSc, Baylor College of Medicine
Antigen Specific T-Cell Therapy

Jeffrey S. Miller, MD, University of Minnesota
Natural Killer Cells to Treat or Prevent Cancer Relapse

Bruce R. Blazar, MD, University of Minnesota
Immune Regulatory Cell Therapies for Graft-Versus-Host Disease
11:05 a.m. – 11:35 a.m.
11:35 a.m. – 12:35 p.m.
Lunch
12:35 p.m. – 2:35 p.m.
Engineered and Non-Engineered T Cells as Tools for Immunotherapy: Beyond CAR T Cells

Chair:
Catherine M. Bollard, MD, Children's National Medical Center

Speakers:
Stephen M. Ansell, MD, PhD, Mayo Clinic
Checkpoint Inhibitors in Lymphoma

Stephen Gottschalk, MD, St. Jude Children's Research Hospital
BiTEs, DARTs, and Other Bispecifics

Ronald Levy, MD, Stanford University
Combining Intratumoral Injections of TLR Agonists With Checkpoint Antibodies

Danielle Townsley, MD, AZ MedImmune
Augmenting the Efficacy of Immunotherapy for Aplastic Anemia
2:35 p.m. – 3:05 p.m.
3:05 p.m. – 3:20 p.m.
Networking Coffee Break
3:20 p.m. – 4:20 p.m.
4:20 p.m. – 6:20 p.m.
Effective Clinical Trial Design in the Field of Immunotherapy

Chair:
Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center

Speakers:
James Kochenderfer, MD, National Cancer Institute, National Institutes of Health
Chimeric Antigen Receptor T Cells: The Balance Between Efficacy and Toxicity

Marcelo C. Pasquini, MD, Medical College of Wisconsin
Developing Cell Therapies in a Cooperative Group Setting

Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center
Checkpoint Blockade in Myeloma, is there a Path Forward?

Yogen Saunthararajah, MD, Cleveland Clinic
Immunotherapies for Myelodysplastic Syndromes: To Modulate or Augment?
6:20 p.m. – 6:50 p.m.
7:00 p.m. – 8:30 p.m.
Welcome and Networking Reception
8:00 a.m. – 4:00 p.m.
Registration
8:00 a.m. – 9:00 a.m.
Breakfast and Exhibits
9:20 a.m. – 10:35 a.m.
Breakout Sessions

Breakout I: Preparing the Garage: How to Prepare for the Commercialization of CAR T Cells


Moderator:
Catherine M. Bollard, MD, Children's National Medical Center

Speakers:
Adrian Gee, PhD, Baylor College of Medicine
GMP Requirements for CAR T Cells

Kristin Baird, MD, U.S. Food and Drug Administration
Regulatory Considerations for Gene Modified T-Cell Therapy

Fabio Fachin, PhD, Torque Therapeutics, and Boro Dropulić, PhD, MBA, Lentigen Technology
Automation and Decentralization of CAR T Cell Manufacture

Breakout II: Toxicity Management: Can We Make This Easier?

Moderator:
Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center

Speakers:
Jennifer Holter Chakrabarty, MD, University of Oklahoma
The Development of Guidelines for Toxicity Management of Checkpoint Inhibitors: What Can We Learn?

James Kochenderfer, MD, National Cancer Institute, National Institutes of Health
Current Standards for Treatment and Prevention of Toxicities Related to CAR T-Cell Therapies

Bianca Santomasso, MD, PhD, Memorial Sloan Kettering Cancer Center
Neurotoxicity: Are There Vulnerable Populations: Very Old or Very Young?

Leslie Kean, MD, PhD, Seattle Children's Research Institute
Biomarkers and Toxicity
11:50 a.m. – 1:00 p.m.
Lunch
1:00 p.m. – 1:50 p.m.
1:50 p.m. – 2:50 p.m.
Reports From Breakout Sessions
3:05 p.m. – 3:50 p.m.
3:50 p.m. – 4:10 p.m.
Closing Remarks From Program Co-Chairs
back to top